Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
UTRECHT, The Netherlands, Nov. 09, 2017 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November 16, 2017 at 4:40 PM GMT at the Waldorf Hilton in London, UK.
A live webcast of the Jefferies presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
[email protected]
Investors:
Kimberly Minarovich
+1 646 368 8014
[email protected]
